New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox &amp; Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (&#34;Embecta&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - July 27, 2026) - <a href="https://api.newsfilecorp.com/redirect/gJgm1sNgKg">Kaplan Fox &#38; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the "Class Period").</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ppVrvs3zN1">CLICK HERE TO JOIN THE CASE</a></p><p><b>If you are an investor in Embecta and have suffered losses, you may </b><a href="https://api.newsfilecorp.com/redirect/YEjLpSxjam"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <u><b>no later than August 17, 2026</b></u> to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p><p>On May 5, 2026, Embecta reported its second quarter fiscal 2026 financial results for the period ending March 31, 2026. The press release stated "[w]e were disappointed with our second quarter results as they were significantly below our expectations." Among other things, Embecta reported second quarter 2026 adjusted earnings per share of $0.27 compared to $0.70 in the prior year period and reduced its fiscal 2026 revenue guidance to a range of between $1.015 billion and $1.035 billion from its previous guidance range of between $1.071 billion and $1.093 billion.</p><p>Following this news, the price of Embecta stock fell $5.35 per share, over 57%, to close at $3.90 per share. </p><p>The complaint alleges, among other things, that Defendants "knew or recklessly disregarded that segment weakness, especially in the United States pen needle market, was likely to disrupt the Company's original revenue guidance and second quarter 2026 results," yet "management reaffirmed guidance during the Company's first quarter 2026 earnings call . . . ."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this Notice, your rights, or your interests, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/0pAgOs5LoY">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/RYNJ5FwND3">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/306717_631b5b6174f308d9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/WAzBwsnzqy">https://www.newsfilecorp.com/release/306717</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/306717/197" alt="" /></p>

EMBC

Kaplan Fox Urges Investors of Embecta Corp. (EMBC) with Significant Losses to Seek a Leadership Role Before August 17, 2026

Embecta Faces Class Action Over Q2 Misses and Pen Needle Weakness

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (&amp;#34;Embecta&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>A Kaplan Fox &amp; Kilsheimer class-action targets Embecta over a Q2 2026 miss and alleged pen-needle weakness. Embecta cut its FY2026 revenue guidance after a disappointing quarter, signaling ongoing demand or mix issues. The stock collapsed about 57% to $3.90, elevating legal-risk concerns and potential volatility near the lead-plaintiff deadline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox filed a class action against Embecta for 11/25/2025–5/4/2026.</li><li>Embecta Q2 FY2026: EPS $0.27; revenue guidance cut to $1.015–$1.035B.</li><li>Stock fell 57% to $3.90 after results.</li><li>Complaint alleges management knew US pen-needle weakness and reaffirmed guidance.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Embecta Corp. (EMBC)</strong>: Primary subject; litigation risk and earnings miss drive near-term volatility.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiff-side law firm; case publicity may heighten perceived litigation risk but no direct market impact.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits as securities litigation coverage around EMBC; potential material impact only if case drives substantial liability or settlement dynamics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Class-action filing could amplify negative sentiment and selling pressure.</li><li>Q2 miss and lower FY2026 guidance pressure multiple and valuation.</li><li>Lead plaintiff deadline August 17, 2026 may trigger volatility.</li><li>EMBC has traded off sharply; additional downside risk remains amid uncertainty.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period: November 25, 2025 to May 4, 2026.</li><li>May 5, 2026: Embecta Q2 fiscal 2026 EPS $0.27 vs $0.70 prior year.</li><li>FY2026 revenue guidance cut to $1.015–$1.035 billion from $1.071–$1.093 billion.</li><li>Stock closed at $3.90 after a $5.35 drop, ~57% fall.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term EMBC volatility rises on legal risk; downside bias until case clarity and earnings trajectory improve.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - July 27, 2026) - <a href="https://api.newsfilecorp.com/redirect/gJgm1sNgKg">Kaplan Fox &#38; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the "Class Period").</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ppVrvs3zN1">CLICK HERE TO JOIN THE CASE</a></p><p><b>If you are an investor in Embecta and have suffered losses, you may </b><a href="https://api.newsfilecorp.com/redirect/YEjLpSxjam"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <u><b>no later than August 17, 2026</b></u> to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p><p>On May 5, 2026, Embecta reported its second quarter fiscal 2026 financial results for the period ending March 31, 2026. The press release stated "[w]e were disappointed with our second quarter results as they were significantly below our expectations." Among other things, Embecta reported second quarter 2026 adjusted earnings per share of $0.27 compared to $0.70 in the prior year period and reduced its fiscal 2026 revenue guidance to a range of between $1.015 billion and $1.035 billion from its previous guidance range of between $1.071 billion and $1.093 billion.</p><p>Following this news, the price of Embecta stock fell $5.35 per share, over 57%, to close at $3.90 per share. </p><p>The complaint alleges, among other things, that Defendants "knew or recklessly disregarded that segment weakness, especially in the United States pen needle market, was likely to disrupt the Company's original revenue guidance and second quarter 2026 results," yet "management reaffirmed guidance during the Company's first quarter 2026 earnings call . . . ."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this Notice, your rights, or your interests, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/0pAgOs5LoY">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/RYNJ5FwND3">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/306717_631b5b6174f308d9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/WAzBwsnzqy">https://www.newsfilecorp.com/release/306717</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/306717/197" alt="" /></p>

A Kaplan Fox & Kilsheimer class-action targets Embecta over a Q2 2026 miss and alleged pen-needle weakness. Embecta cut its FY2026 revenue guidance after a disappointing quarter, signaling ongoing demand or mix issues. The stock collapsed about 57% to $3.90, elevating legal-risk concerns and potential volatility near the lead-plaintiff deadline.

News insight

Kaplan Fox Urges Investors of Embecta Corp. (EMBC) with Significant Losses to Seek a Leadership Role Before August 17, 2026

AI summary

Sentiment rationale

Key facts

Legal